The GLP is committed to full transparency. Download and review our 2019 Annual Report

Rare brain disorder—Angelman syndrome—could be treated with gene therapy in the womb

| | February 22, 2019
2-19-2019 angelman clinic feature
Child with Angelman syndrome. Image credit: Rush University Medical Center
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Scientists are developing a radical form of gene therapy that could cure a devastating medical disorder by mending mutations in the brains of foetuses in the womb.

The treatment, which has never been attempted before, would involve doctors injecting the feotus’s brain with a harmless virus that infects the neurons and delivers a suite of molecules that correct the genetic faults.

The therapy is aimed at a rare brain disorder known as Angelman syndrome, which affects one in 15,000 births. Children with the condition have small brains and often experience seizures and problems with walking and sleeping. They can live their whole lives without speaking a word.

Related article:  Transgenic GMOs will remain banned in Italy, agriculture minister says, but cisgenic gene editing could help sustain nation's crop diversity

In Angelman syndrome, the mother’s copy of UBE3A is either missing or mutated, meaning there is no UBE3A active at all. Zylka’s therapy uses a version of a powerful gene editing tool known as Crispr-Cas9 to switch the father’s copy back on [in mice].

Follow-up work showed that it worked in human brain cells grown in a dish, too. “It really does raise the possibility that this gene therapy might be usable in humans,” [neurobiologist Mark] Zylka said.

Read full, original post: Gene therapy could treat rare brain disorder in unborn babies

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend